APA (7th ed.) Citation

J, D., F, H., MN, N., H, C., D, L., M, T., . . . G, L. (2010). Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. Clinical therapeutics, 32(11), 1889. https://doi.org/10.1016/j.clinthera.2010.10.007

Chicago Style (17th ed.) Citation

J, Davis, Hackman F, Ndongo MN, Choo H, Lewis D, Tawadrous M, Goodrich J, and Langdon G. "Safety and Tolerability of Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor, During a 28-day, Randomized, Placebo-controlled, Phase I Clinical Study in Healthy Male Volunteers." Clinical Therapeutics 32, no. 11 (2010): 1889. https://doi.org/10.1016/j.clinthera.2010.10.007.

MLA (9th ed.) Citation

J, Davis, et al. "Safety and Tolerability of Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor, During a 28-day, Randomized, Placebo-controlled, Phase I Clinical Study in Healthy Male Volunteers." Clinical Therapeutics, vol. 32, no. 11, 2010, p. 1889, https://doi.org/10.1016/j.clinthera.2010.10.007.